2 models fit The Beauty Health Company Class A Common Stock and they agree: 2 of 2 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Bronze48
Valued as a growth company: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
ACCE opinionThe Beauty Health Company Class A Common Stock (SKIN)
Fair value (2 models)
$38.21
ACCE price target
$9.50
Rating
Undervalued
Horizon
12 months
Fair value published on 16 Oct 2026, 00:00 CEST; previously $1.81 since 15 Oct 2026, 00:00 CEST.
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $10.88 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
71.5% below
+251.2% to fair value
ACCE score
42
out of 100
Analysts
11% buy
9 covering
P/E
0.0x
forward 106.4x
1-year return
-58.2%
Dividend yield
0.00%
The Beauty Health Company Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
The Beauty Health Company makes the HydraFacial device and its consumable solutions, which are used by aestheticians and dermatologists for in-office skin treatments, alongside a smaller at-home line. The core advantage is the installed base of professional systems and the recurring consumables sold into it, which supports the 66.4% gross margin. Revenue is shrinking, though, down 7.8%, and the business only just reached a 5.0% operating margin. The return on equity of -43.9% and a forward P/E above 100 leave little room for error, so this is a name to examine only if you believe the margin recovery is durable and the top line stabilises. At an $82M market cap with no index membership, the stock is small and illiquid enough that position sizing would need care.